News
COSM
0.2633
+5.40%
0.0135
Cosmos Health's Cana Laboratories Signs 5-Year EU Manufacturing Deal With Pharmex To Produce 2.86M Units Of Prescription Dermatology Products
Benzinga · 9h ago
Cosmos Health signs 5-year Pharmex contract manufacturing deal for 2.86 million dermatology product units
PUBT · 9h ago
COSMOS HEALTH - ENTERS FIVE-YEAR CONTRACT MANUFACTURING AGREEMENT WITH PHARMEX
Reuters · 9h ago
Cosmos Health CFO Georgios Terzis acquires 168,135 common shares valued at $42,000
PUBT · 9h ago
Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
Barchart · 14h ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 2d ago
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins
Benzinga · 2d ago
Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform
Benzinga · 2d ago
Weekly Report: what happened at COSM last week (0608-0612)?
Weekly Report · 2d ago
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Cosmos Holdings CEO Quietly Ramps Up His Stake in a Big Way
TipRanks · 4d ago
Cosmos Health’s Cana wins contract manufacturing orders totaling 253,657 units
TipRanks · 5d ago
Cosmos Health Subsidiary Gets New Production Order Contracts From Nassington, Verisfield For 253,657 Units Throughout Range of Medicines, Other Pharmaceutical Products
Benzinga · 5d ago
Cosmos Health unit Cana receives contract manufacturing orders for 253,657 medicine units
PUBT · 5d ago
COSMOS HEALTH RECEIVES NEW CONTRACT MANUFACTURING ORDERS TOTALING 253,657 UNITS ACROSS A RANGE OF MEDICINES
Reuters · 5d ago
Cosmos Health CEO Grigorios Siokas acquires $45,000 in common shares
PUBT · 5d ago
Cosmos Health Expands Antiseptic Brands Across Europe; Stock Up
NASDAQ · 5d ago
Cosmos Health Reports Trailing 12-Month C-Scrub And C-Sept Segment Sales Of $1.5M+ With Gross Margins Of 70%+
Benzinga · 5d ago
Cosmos Health targets 2028 C-Scrub, C-Sept revenue of about $7.4 million
PUBT · 5d ago
COSMOS HEALTH REPORTS ANNUALIZED SALES EXCEEDING $1.5M FOR ITS C-SCRUB AND C-SEPT ANTISEPTIC BRANDS IN THE UK AND GREECE; PLANS EU EXPANSION TARGETING $7.4M IN REVENUE AND $5.3M IN GROSS PROFIT
Reuters · 5d ago
More
Webull provides a variety of real-time COSM stock news. You can receive the latest news about Cosmos Health Inc. through multiple platforms. This information may help you make smarter investment decisions.
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.